Table 2 Clinical characteristics of the 384 subjects of our study cohort by ATS/IDSA criteria
|  | Total cohort (n = 384) | ATS/IDSA + (n = 165) | ATS/IDSA - (n = 219) | ORa [CI 95%] | aORb [CI 95%] |
|---|---|---|---|---|---|
Demography | n (%) | n (%) | n (%) | Â | Â |
Median age in years (IQR)c | 65 (54–74) | 64 (52–74) | 67 (55–75) | – | – |
Male | 232 (60.4%) | 94 (57%) | 138 (63%) | 0.78 [0.51–1.17] | – |
Smoking historyd | 217 (56.5%) | 96 (58.2%) | 121 (55.3%) | 1.03 [0.68–1.57] | – |
Comorbiditye | |||||
 Non-CF bronchiectasis | 60 (15.6%) | 33 (20%) | 27 (12.3%) | 1.74 [1.00–3.03] | – |
 Cystic fibrosis | 24 (6.3%) | 10 (6.1%) | 14 (6.4%) | 0.93 [0.40–2.14] | – |
 COPD/emphysema | 159 (41.4%) | 69 (41.8%) | 90 (41.1%) | 1.00 [0.66–1.51] | – |
 Previous NTM disease | 31 (8.1%) | 23 (13.9%) | 8 (3.7%) | 4.19 [1.82–9.63] | – |
 Previous TB disease | 32 (8.3%) | 12 (7.3%) | 20 (9.1%) | 0.76 [0.36–1.61] | – |
 Pulmonary aspergillosis | 16 (4.2%) | 7 (4.2%) | 9 (4.1%) | 1.01 [0.37–2.78] | – |
 Gastroesophageal reflux | 28 (7.3%) | 8 (4.8%) | 20 (9.1%) | 0.50 [0.21–1.16] | – |
 Active malignancy | 63 (16.4%) | 28 (17%) | 35 (16%) | 1.05 [0.61–1.81] | – |
 Immunodeficiency | 91 (23,7%) | 44 (26,7%) | 47 (21.5%) | 1.30 [0.81–2.09] | – |
 Transplantation | 22 (5.7%) | 9 (5.5%) | 13 (5.9%) | 0.90 [0.37–2.15] | – |
 Other | 127 (33.1%) | 52 (31.5%) | 75 (34.2%) | 0.86 [0.56–1.33] | – |
Symptomatologyf | |||||
 Fever | 68 (17.7%) | 40 (24.2%) | 28 (12.8%) | 2.11 [1.24–3.61] | 2.26 [1.12–4.56] |
 Night sweats | 30 (7.8%) | 20 (12.1%) | 10 (4.6%) | 2.80 [1.27–6.16] | – |
 Fatigue/malaise | 109 (28.4%) | 63 (38.2%) | 46 (21%) | 2.24 [1.43–3.53] | – |
 Sputum | 192 (50%) | 90 (54.5%) | 102 (46.6%) | 1.31 [0.87–1.96] | – |
 Chest pain | 41 (10.7%) | 20 (12.1%) | 21 (9.6%) | 1.26 [0.66–2.41] | – |
 Cough | 278 (72.4%) | 135 (81.8%) | 143 (65.3%) | 2.20 [1.35–3.59] | – |
 Dyspoea | 186 (48.4%) | 77 (46.7%) | 109 (49.8%) | 0.84 [0.56–1.25] | – |
 Weight loss | 108 (28.1%) | 71 (43%) | 37 (16.9%) | 3.59 [2.25–5.74] | 2.47 [1.42–4.31] |
 Hemoptysis | 63 (16.4%) | 35 (21.2%) | 28 (12.8%) | 1.78 [1.03–3.07] | – |
 Other | 31 (8.1%) | 11 (6.7%) | 20 (9.1%) | 0.69 [0.32–1.48] | – |
Radiology (chest CT)g | |||||
 Fibrocavitary lesions | 63 (16.4%) | 46 (27.9%) | 17 (7.8%) | 4.45 [2.44–8.12] | 11.0 [4.74–25.57] |
 Nodular bronchiectatic lesions | 188 (49%) | 103 (54.8%) | 85 (38.8%) | 2.50 [1.64–3.81] | 7.34 [3.87–13.91] |
 Other | 124 (32.3%) | 15 (12.1%) | 109 (49.8%) | 0.094 [0.052–0.17] | – |
Microbiology | |||||
 AFB staining positive | 78 (20.3%) | 64 (38.8%) | 14 (6.4%) | 9.28 [4.96–17.34] | 5.20 [2.60–10.42] |
 Pseudomonas aeruginosah | 54 (14.1%) | 24 (14.5%) | 30 (13.7%) | 1.07 [0.60–1.90] | – |
 Aspergillus fumigatush | 70 (18.2%) | 42 (25.5%) | 28 (12.8%) | 2.32 [1.37–3.93] | – |